Physician profile
Paul Dillon
NPI 1184662033
$1,495.32
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $531 · 2021: $306.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $425.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $188.57 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $121.24 | 2019-2021 | |
| Amarin Pharma, INC. | $97.93 | 2020-2021 | |
| Amgen INC. | $95.77 | 2019-2021 | |
| Pfizer INC. | $67.89 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $58.93 | 2019 | |
| Genentech USA, INC. | $55.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.50 | 2019-2020 | |
| Lilly USA, LLC | $50.20 | 2019-2021 | |
| Shire North American Group INC | $30.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.37 | 2019 | |
| Glaxosmithkline, LLC. | $15.88 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.43 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.54 | 2021 | |
| Adlon Therapeutics L.P. | $14.39 | 2020 | |
| Abbvie INC. | $13.79 | 2021 | |
| Daiichi Sankyo INC. | $12.32 | 2019 | |
| Sanofi Pasteur INC. | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.